ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $300,786 | -47.7% | 11,194 | -30.6% | 0.00% | 0.0% |
Q2 2023 | $574,879 | +23.8% | 16,121 | +40.8% | 0.00% | 0.0% |
Q4 2022 | $464,290 | +18.7% | 11,447 | -3.2% | 0.00% | 0.0% |
Q3 2022 | $391,000 | +18.1% | 11,820 | +25.9% | 0.00% | 0.0% |
Q2 2022 | $331,000 | -24.4% | 9,390 | -1.5% | 0.00% | 0.0% |
Q1 2022 | $438,000 | -50.3% | 9,534 | -28.3% | 0.00% | -50.0% |
Q4 2021 | $881,000 | +4.0% | 13,291 | -2.0% | 0.00% | 0.0% |
Q3 2021 | $847,000 | -25.8% | 13,561 | -1.7% | 0.00% | -33.3% |
Q2 2021 | $1,142,000 | -42.9% | 13,790 | -50.7% | 0.00% | -40.0% |
Q1 2021 | $2,001,000 | -8.9% | 27,984 | -2.2% | 0.01% | -16.7% |
Q4 2020 | $2,196,000 | +237.8% | 28,619 | +89.5% | 0.01% | +200.0% |
Q3 2020 | $650,000 | +40.1% | 15,104 | +40.7% | 0.00% | +100.0% |
Q2 2020 | $464,000 | -59.7% | 10,734 | -40.9% | 0.00% | -66.7% |
Q4 2019 | $1,151,000 | +70.0% | 18,150 | -24.5% | 0.00% | +50.0% |
Q3 2019 | $677,000 | – | 24,036 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |